Key Influenza Vaccine Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The highly competitive environment is experienced by the key players of the influenza vaccine global market. Companies like Sanofi, GSK, and CSL Seqirus dominated the global market with a hold of more than 60% of the market share. The key strategies followed by the companies to gain competitiveness include mRNA vaccine development by companies like Pfizer and Moderna, which ensured better patient outcomes and vaccine efficacy. Business expansion in the emerging market is conducted by Serum Institute and Sinovac, which has generated low-cost production and accelerated the revenue generation scope. Companies like Takeda and Bio Pharma aligned with the government partnership and boosted the market penetration and procurement contracts. The vertical integration strategy is also followed by GSK and Abbott to gain regional dominance through a combination of providing vaccines and diagnostics.
Here are some leading players in the global influenza vaccine market:
|
Company Name |
Industry Focus |
Market Share (2024) |
|
Sanofi (France) |
Leader in flu vaccines and investing in mRNA and cell-based tech. |
25.2% |
|
GSK (UK) |
Produces Fluarix/FluLaval; |
20.4% |
|
CSL Seqirus (Australia/U.S.) |
produces Afluria and cell-based Flucelvax. |
18.3% |
|
Abbott (U.S.) |
Rapid flu diagnostics + vaccine R&D |
10.4% |
|
Pfizer (U.S.) |
mRNA flu vaccine development |
8.4% |
|
Sinovac Biotech (China) |
Dominates China’s market; supplies WHO-prequalified flu vaccines. |
xx% |
|
Takeda Pharmaceuticals (Japan) |
Produces TAK-850 |
xx% |
|
Serum Institute of India (India) |
low-cost flu vaccines for LMICs. |
xx% |
|
Serum Institute of India (India) |
Focus on intranasal and pandemic-ready flu vaccines. |
xx% |
|
Bharat Biotech (India) |
Developing mRNA-based flu vaccines (Phase 3 trials). |
xx% |
|
Moderna (U.S.) |
Protein-based NanoFlu vaccine; |
xx% |
|
Novavax (U.S.) |
Supplies Japan’s public health programs with influenza vaccines. |
xx% |
|
Daiichi Sankyo (Japan) |
Leading Korean manufacturer; |
xx% |
|
Green Cross Corp (South Korea) |
Leader in flu vaccines (Fluzone, Vaxigrip), |
xx% |
|
Hualan Biological (China) |
Major supplier in China; expanding in emerging markets. |
xx% |
|
Bio Farma (Indonesia) |
State-owned producer; |
xx% |
|
KM Biologics (Japan) |
Specializes in egg-based flu vaccines for Japan & Asia. |
xx% |
|
Baxter International. (U.S.) |
Historical player in flu vaccines; |
xx% |
|
Merck & Co. (U.S.) |
Limited flu vaccine portfolio but strong in adjuvants. |
xx% |
|
LG Chem (South Korea) |
Expanding vaccine division; |
xx% |
|
Pharmaniaga (Malaysia) |
Government-backed; supplies Malaysia’s national immunization program. |
xx% |
Below are the areas covered for each company in the influenza vaccine market:
